Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule
暂无分享,去创建一个
Dietmar Hoffmann | Jean-Pierre Marquette | Magali Mathieu | Stuart Licht | Olivier Bedel | Ying Zhang | Francisco Adrian | Larry R. McLean | Bailin Zhang | Qiang Gao | Gejing Deng | S. Gross | Q. Gao | D. Wiederschain | M. Mathieu | Ying Zhang | S. Licht | A. Rak | E. Rooney | F. Adrián | O. Bedel | G. Deng | Bailin Zhang | Timothy He | D. Hoffmann | Hong Cheng | L. McLean | J. Marquette | Dmitri Wiederschain | Stefan Gross | Alexey Rak | Timothy He | Walter Englaro | Hong Cheng | Junqing Shen | Chaomei Shi | P. Gee | Ming Yin | Jessica McManus | Patricia Gee | Frank Le-Strat | Eamonn Rooney | Aurelie Vassort | Yi Li | Vinod Patel | Chaomei Shi | Jessica Mcmanus | M. Yin | Walter Englaro | Aurélie Vassort | Vinod F. Patel | Junqing Shen | Frank Le-Strat | Yi Li | Dietmar Hoffmann | Olivier Bedel
[1] S. Su,et al. IDH mutations in glioma and acute myeloid leukemia. , 2010, Trends in molecular medicine.
[2] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[3] Frank M. Sacks,et al. IDH 1 and IDH 2 Mutations in Gliomas , 2009 .
[4] K. Wagner,et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Manuela Zucknick,et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Mindy I. Davis,et al. Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1* , 2014, The Journal of Biological Chemistry.
[7] Jack Snoeyink,et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids , 2007, Nucleic Acids Res..
[8] Fang Wang,et al. Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.
[9] Nicholas D. Adams,et al. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism. , 2013, Biochemistry.
[10] B. Prasad,et al. Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. , 2013, ACS medicinal chemistry letters.
[11] S. Gross,et al. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. , 2012, ACS medicinal chemistry letters.
[12] E. Gottlieb,et al. Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.
[13] N. Grodsky,et al. Crystal Structure of Porcine Mitochondrial NADP+-dependent Isocitrate Dehydrogenase Complexed with Mn2+ and Isocitrate , 2002, The Journal of Biological Chemistry.
[14] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[15] Jianping Ding,et al. Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H , 2010, Cell Research.
[16] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[17] R. Grubbs. Intracellular magnesium and magnesium buffering , 2002, Biometals.
[18] A. Levine,et al. The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.
[19] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[20] Michael Heuser,et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. , 2010, Blood.
[21] J. Yon,et al. Enzyme Kinetics behavior and Analysis of rapid equilibrium and steady state enzyme systems, I.H. Segel. John Wiley, London (1975) , 1976 .
[22] Fang Wang,et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.
[23] Jianping Ding,et al. Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity* , 2004, Journal of Biological Chemistry.
[24] R. Verhaak,et al. Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.
[25] Joseph G Boyer,et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. , 2011, Biochemistry.
[26] I. H. Segel. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .
[27] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[28] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[29] Kun-Liang Guan,et al. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.
[30] Hai Yan,et al. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. , 2010, Journal of the National Cancer Institute.
[31] Bangguo Wei,et al. BF3·Et2O catalyzed diastereoselective nucleophilic reactions of 3-silyloxypiperidine N,O-acetal with silyl enol ether and application to the asymmetric synthesis of (+)-febrifugine , 2009 .
[32] De-Qi Yuan,et al. Direct Imidazolylmethylation of Phenols , 1994 .
[33] B. Geisbrecht,et al. The Human PICD Gene Encodes a Cytoplasmic and Peroxisomal NADP+-dependent Isocitrate Dehydrogenase* , 1999, The Journal of Biological Chemistry.
[34] R. Klose,et al. The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.
[35] G. Jennings,et al. Expression of pig heart mitochondrial NADP-dependent isocitrate dehydrogenase in Escherichia coli. , 1996, Protein Expression and Purification.
[36] J. Kelly,et al. Synthesis of all nineteen appropriately protected chiral alpha-hydroxy acid equivalents of the alpha-amino acids for Boc solid-phase depsi-peptide synthesis. , 2004, Organic letters.